Hepatitis C infected kidneys safe for Dialysis patients as researchers from Johns Hopkins have devised a cure which would permit them to be utilized for dialysis patients in despairing need for a transplant. In a study conducted, ten kidney patients were medicated before transplant surgery with an anti-viral medication that halts Hepatitis C from duplicating in the body and sustained receiving treatment for 12 weeks after transplant, according to Dr. Niraj Desai, director of the kidney and transplant program at Johns Hopkins University in Baltimore. The patients were already ill and had passed years waiting for a kidney transplant. They all had been diagnosed with stage 5 chronic kidney disease and there was no feasible living donor.

This trial was hazardous for the patients. They would obtain a much required kidney but could be contaminated by with the disease and would be a permanent affliction. During the program, the patients were incessantly observed with a blood test to quantify the amount of hepatitis C virus was present in their blood. All the ten patients were void of the virus after apprehending the 12-week course of the oral medication, Zepatier.

Desai said that it hardly deciphers our kidney paucity problem but it has the possibility to sanction 500 to 1,000 more people to kidney transplants depended on how many organs are being abandoned now. Of the ten patients five showcased an unnoticeable viral load from the disease succeeding surgery. After the 12 weeks of cure, none of the 10 showed any sign of the disease.